Companies › Xynomic Pharmaceuticals
2 active drug programs in 19 registered trials: 8 Phase 2, 8 Phase 1, 3 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Abexinostat Histone deacetylase inhibitor | HDAC (class I/II) | Phase 3 | Renal Cell Carcinoma; Lymphoma, Follicular; Diffuse Large B-cell Lymphoma (DLBCL); Follicular Lymphoma … | Dec 2026 |
| Pazopanib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor | CSF1R, KIT, LCK, FGFR3, FGFR1 | Phase 3 | Renal Cell Carcinoma; Leiomyosarcoma or Carcinosarcoma; Soft Tissue Sarcoma; Rhabdomyosarcoma, Recurrent, Refractory … | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04024696 | Abexinostat | Phase 1 | Non Hodgkin Lymphoma | Oncology | Dec 2024 |
| NCT02203760 | Pazopanib | Phase 2 | Leiomyosarcoma or Carcinosarcoma | Oncology | Dec 2024 |
| NCT02203760 | Pazopanib | Phase 2 | Leiomyosarcoma or Carcinosarcoma | Oncology | Dec 2024 |
| NCT03934567 | Abexinostat | Phase 2 | Lymphoma, Follicular | Oncology | Jan 2025 |
| NCT06895733 | Pazopanib | Phase 1 | Solid Tumor, Adult | Oncology | Dec 2025 |
| NCT03592472 | Abexinostat | Phase 3 | Renal Cell Carcinoma | Oncology | Dec 2026 |
| NCT03592472 | Pazopanib | Phase 3 | Renal Cell Carcinoma | Oncology | Dec 2026 |
| NCT05679921 | Pazopanib | Phase 2 | Soft Tissue Sarcoma | Oncology | Dec 2026 |
| NCT06816771 | Pazopanib | Phase 2 | Rhabdomyosarcoma, Recurrent, Refractory | Oncology | Dec 2026 |
| NCT05180695 | Pazopanib | Phase 1 | Advanced Soft-tissue Sarcoma | Oncology | Feb 2027 |
| NCT02331498 | Pazopanib | Phase 1 | Glioblastoma Multiforme | Oncology | Feb 2027 |
| NCT05698524 | Abexinostat | Phase 1 | Recurrent High Grade Glioma | Oncology | Jul 2027 |
| NCT03936153 | Abexinostat | Phase 2 | Diffuse Large B-cell Lymphoma (DLBCL) | Oncology | Aug 2027 |
| NCT05210413 | Pazopanib | Phase 1 | Refractory or Recurrent Solid Tumor | Oncology | Nov 2027 |
| NCT03600441 | Abexinostat | Phase 2 | Follicular Lymphoma | Oncology | Dec 2027 |
| NCT01217931 | Pazopanib | Phase 2 | Kidney Cancer | Oncology | Jan 2028 |
| NCT01224288 | Pazopanib | Phase 3 | Renal Cell Carcinoma | Oncology | Apr 2029 |
| NCT07444619 | Pazopanib | Phase 1 | Soft Tissue Sarcomas | Oncology | Dec 2031 |
| NCT06239272 | Pazopanib | Phase 1 | Adipocytic Neoplasm | Oncology | Jun 2034 |
Daiichi Sankyo Tyra Biosciences Deciphera Pharmaceuticals Exelixis Blueprint Medicines AstraZeneca Johnson & Johnson (Janssen) Hutchmed Novartis Gossamer Bio USA
Acrotech Biopharma LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company Quercis Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.